
Oncode Accelerator is a public-private partnership funded by the Dutch National Growth Fund, dedicated to revolutionizing preclinical cancer therapy development. It centers patients by leveraging three Innovation Platforms: Patient Cohorts, Organoid models, and Artificial Intelligence, integrated into the development of Small Molecules, Biologics, Cell & Gene Therapy, and Therapeutic Vaccines. The organization aims to collaboratively optimize and accelerate the development of new cancer therapies, fostering a community of over 35 public and private partners across six coordinating institutions. With €325 million invested by the National Growth Fund, the program is budgeted for €662 million from 2022 to 2030, launching in September 2023 with the goal of establishing the Netherlands as a leader in the oncology therapy market.

Oncode Accelerator is a public-private partnership funded by the Dutch National Growth Fund, dedicated to revolutionizing preclinical cancer therapy development. It centers patients by leveraging three Innovation Platforms: Patient Cohorts, Organoid models, and Artificial Intelligence, integrated into the development of Small Molecules, Biologics, Cell & Gene Therapy, and Therapeutic Vaccines. The organization aims to collaboratively optimize and accelerate the development of new cancer therapies, fostering a community of over 35 public and private partners across six coordinating institutions. With €325 million invested by the National Growth Fund, the program is budgeted for €662 million from 2022 to 2030, launching in September 2023 with the goal of establishing the Netherlands as a leader in the oncology therapy market.